Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBioquell Regulatory News (BQE)

  • There is currently no data for BQE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Re Contract

27 Jun 2011 07:00

RNS Number : 1079J
Bioquell PLC
27 June 2011
 



 

 

27 June, 2011

 

 

BIOQUELL PLC

Completion of the registration of Bioquell China

Award of c. US$ 1 million contract for specialist bio-decontamination equipment to be used by the Chinese Ministry of Agriculture

 

Bioquell PLC (LSE: BQE) ("Bioquell") - provider of specialist low temperature, residue-free bio-decontamination technologies to the healthcare, life sciences and defence sectors - announces that the Chinese authorities have completed the approvals necessary for the registration of Bioquell China.

In addition, Bioquell announces that it has been awarded a contract to supply specialist hydrogen peroxide vapour bio-decontamination equipment to research organisations within the Chinese Government's Ministry of Agriculture worth approximately US$1 million. This bio-decontamination equipment is scheduled to be shipped in the second half of the year - and will be installed and serviced by Bioquell China.

 

Commenting on this contract award in China, Nick Adams, Group Chief Executive of Bioquell PLC, said:

"We are delighted to have won a significant first contract for our unique hydrogen peroxide vapour bio-decontamination equipment from Chinese government research organisations."

"This contract award helps demonstrate the benefits of our substantial investment in the Asia Pacific region - and specifically the establishment of Bioquell China."

 

- Ends -

 

 

Enquiries:

 

Bioquell PLC 01264 835 900

Nick Adams Group Chief Executive

Mark Bodeker Chief Operating Officer / Finance Director

 

Notes to editors:

§ Bioquell is a UK-headquartered, international technology company with two divisions:

o Bio-decontamination which sells specialist bio-decontamination products and services into the Healthcare, Life Sciences and Defence sectors, with most of its revenues generated from overseas customers; and

o TRaC which provides UK corporates with specialist Testing, Regulatory and Compliance services - many of which are required by national and international regulations.

§ Bioquell's gas phase bio-decontamination technology uses hydrogen peroxide vapour - which is highly efficacious at eradicating micro-organisms such as bacteria, viruses and fungi at room temperature - and is subsequently broken down using specialist catalysts to water vapour and oxygen at the end of the bio-decontamination process.

§ Bioquell's bio-decontamination technology:

o is used by bio-pharmaceutical, biologics, biotechnology and research institutions to provide sterile equipment and/or sterile working environments - which is of particular interest to organisations working with biologically-derived drugs;

o is also used by researchers involved in the study of zoonotic transfer whereby diseases in animals can be transferred to humans - with examples including SARS (which is believed to have originated in China) and porcine swine fever (which originated in Mexico)

o is used to eradicate drug resistant organisms associated with Hospital Acquired Infection as well as problematic viruses from the hospital environment. Independent scientific research has demonstrated that 'bioquelling' hospital equipment and facilities reduces the rates of hospital acquired infection;

o was selected by the United States Department of Defense for the JSSED programme to decontaminate sensitive equipment against biological and chemical warfare agents;

o benefits from a number of granted or pending patent filings in the UK and internationally;

o is used in other sectors where bioburden can create significant problems including, for example, the food industry; and

o also comprises specialist filtration technology including peroxide catalysis and chemical, biological, radiological and nuclear ("CBRN") filtration systems used principally in the defence sector.

§ Bioquell currently has overseas operations in the USA, France, Ireland, Singapore and China.

§ TRaC sells its specialist testing services to the product development and engineering departments of a broad range of companies and organisations, principally based in the UK, with a particular focus on the aerospace, military and telecoms sectors.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTSESFILFFSESM
Date   Source Headline
23rd Feb 20128:22 amRNSHolding(s) in Company
2nd Dec 20117:00 amRNSRe Contract
18th Nov 20117:00 amRNSInterim Management Statement
3rd Oct 20112:13 pmRNSCapital Reorganisation
31st Aug 20117:00 amRNSHalf Yearly Report
29th Jun 20117:00 amRNSRe Contract
27th Jun 20117:00 amRNSRe Contract
27th Jun 20117:00 amRNSCapital Reorganisation
16th May 20112:34 pmRNSResult of AGM
16th May 20117:00 amRNSInterim Management Statement
19th Apr 201110:00 amRNSDirector/PDMR Shareholding
12th Apr 20118:31 amRNSAnnual Financial Report
23rd Mar 201110:15 amRNSDirector/PDMR Shareholding
15th Mar 20117:00 amRNSAnnual Financial Report
22nd Nov 20103:14 pmRNSHolding(s) in Company
19th Nov 20107:00 amRNSInterim Management Statement
8th Sep 20107:00 amRNSRe Contract
2nd Sep 201010:40 amRNSDirector/PDMR Shareholding
1st Sep 20109:00 amRNSDirector/PDMR Shareholding
27th Aug 20107:00 amRNSDirectorate Change
27th Aug 20107:00 amRNSHalf Yearly Report
18th May 201011:08 amRNSResult of AGM
14th May 20109:16 amRNSDirector/PDMR Shareholding
10th May 20107:00 amRNSInterim Management Statement
15th Apr 20108:45 amRNSAnnual Financial Report
19th Mar 20104:43 pmRNSDirector/PDMR Shareholding
19th Mar 201011:02 amRNSGrant of Options to Directors - Correction
18th Mar 20104:29 pmRNSStatement re Grant of Options to Directors
16th Mar 20107:00 amRNSFinal Results
19th Nov 20097:00 amRNSInterim Management Statement
28th Oct 20093:41 pmRNSHolding(s) in Company
27th Oct 20093:58 pmRNSHolding(s) in Company
16th Oct 20097:00 amRNSRe Contract
18th Aug 20097:00 amRNSHalf Yearly Report
28th May 20095:15 pmRNSAGM
19th May 20097:00 amRNSInterim Management Statement
28th Apr 20098:58 amRNSDirector/PDMR Shareholding
27th Mar 20093:15 pmRNSDirector/PDMR Shareholding
24th Mar 20097:00 amRNSFinal Results
13th Nov 20087:30 amRNSInterim Management Statement
5th Sep 200810:02 amRNSDirector/PDMR Shareholding
27th Aug 20087:27 amRNSInterim Results
16th Jul 20089:38 amRNSHolding(s) in Company
1st Jul 20088:39 amRNSDirector/PDMR Shareholding
28th May 20084:41 pmRNSDirectors' share options
27th May 20084:49 pmRNSResult of EGM
27th May 20084:44 pmRNSResult of AGM
19th May 20087:00 amRNSInterim Management Statement
4th Apr 20081:07 pmRNSNotice of EGM
25th Mar 200811:24 amRNSDirectors' option exercise

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.